EIT Health-backed Smart4Diagnostics (S4DX) has just announced the successful closing of up to 3.6 million euros in a bridge financing round. The funding comes from private investors including VP Venture Partners and the SARSTEDT AG & Co. KG. The money will be used to scale the S4DX digital pre-analytical monitoring system within Europe and globally.
S4DX formed in 2018 as part of the EIT Health Wild Card program, which focuses on building game-changing life science companies to break new ground in health by challenging the status quo in areas of high unmet need. Since then, the company has further developed its “digital human blood sample fingerprint”, a complete data-picture of all quality aspects for human samples from collection to arrival in the lab. All relevant pre-analytical data points are collected in real time and can be integrated seamlessly into any laboratory information system or laboratory analyzer middleware.
“In the last three years, the S4DX system has become the market leading system for digital preanalytical sample monitoring in Europe. Already today the system is live in ten countries. Now it’s the right time to scale globally, together with our strong partners. We want to make digital preanalytics a reality for all – for the benefit of patients, phlebotomists and everybody involved in Diagnostics and Science”, comments Dr. Hans Maria Heyn, CEO and co-founder of S4DX.
Combined with its unique and adaptive transport monitoring, the S4DX system allows for preanalytical errors to be identified and corrected immediately, therefore not only increasing preanalytical sample quality but also significantly reducing time and cost for laboratories at sample entry.
To scale globally, Smart4Diagnostics has strategic partnerships with world leading diagnostic companies such as Sarstedt, Beckman Coulter and Roche Diagnostics. .
“We are immensely proud of all that the S4DX team has achieved, including the latest funding round. This is an exceptional case of building a digital solution that is the foundation for digital transformation of an entire industry. This will change how we deal with human samples in the future.” concludes Dr. Valentin Piëch, Board Member for VP Venture Partners.